Fig. 3

Uptake of FMC-EV expressing CD63-GFP in vivo and in vitro. A Observation of CD63-GFP expression in vesicles in CD63-GFP-expressing FMC-1807 cells by epifluorescence microscopy. Bar, 10 μm. B Representative IVIS-imaging data of the primary tumor, lung, liver, spleen, and kidneys taken from FMC-xenograft-bearing mice, which had been intraperitoneally injected with CD63-GFP-expresing EV or PBS (control) 12 or 24 h earlier. C Flow cytometry analysis of uptake of CD63-GFP-expressing EV in various types of cells. FMC-1807, LX-2 (human hepatic stellate cell, HSC), BNL CL.2 and FL83B (mouse hepatocyte), RAW 264.7 (mouse macrophage), SVEC4-10 (mouse endothelial cell), and NMuMG (mouse mammary epithelial cell) were incubated with CD63-GFP-expressing EV (1 × 10⁹ EV particles/1 × 10⁴ cells) for 30 min and subsequently analyzed by flow cytometry. The percentage of GFP-positive cells of each cell type (n = 3) was presented as the mean ± SD